Multiplatform Pipeline
Transactions & Partnerships
In November 2023, Bristol Myers Squibb acquired ORM-6151/BMS-986497 at a total deal value of $180 million. ORM-6151/BMS-986497 is a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader initially developed by Orum Therapeutics for the treatment of acute myeloid leukemia (AML) and other CD33-expressing malignancies.
Partnering with Orum
Do you have targets and antibodies that might work well with our payload platforms? Or have you developed degraders that need a better therapeutic index via antibody delivery? Orum is ready to discuss a variety of different collaboration possibilities across our TPD² and TPS² platforms and programs. Please contact us and let us know how we can work together.
Meet the Orum Business Development Team at:
JP Morgan Healthcare Conference – January 8-11, San Francisco, CA, USA